Adalimumab is a biologic medication used to treat several inflammatory and autoimmune conditions. It works by blocking tumor necrosis factor alpha, a protein involved in inflammation. Although treatment can help manage symptoms, it may cause side effects and interact with certain medications. Understanding potential risks, infection concerns, and precautions can help patients discuss treatment options with healthcare professionals.
Adalimumab is a tumor necrosis factor (TNF) blocker prescribed for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, ulcerative colitis, and certain other inflammatory disorders. By reducing TNF activity, it helps control inflammation. However, suppressing part of the immune system can increase susceptibility to infections and other complications.
Common side effects include injection site reactions, headaches, and upper respiratory infections. The likelihood and severity of adverse effects can vary depending on individual health circumstances and other medications.
Injection site reactions: Redness, swelling, itching, bruising, or discomfort may occur where the medicine is injected.
Infections: Patients may experience respiratory infections or other infections. Serious infections, including tuberculosis and certain fungal infections, are also possible.
Allergic reactions: Rash, swelling, breathing difficulties, or other symptoms of a serious allergic reaction require prompt medical attention.
Blood and nervous system complications: Rarely, treatment may be associated with blood disorders or new or worsening demyelinating diseases affecting the nervous system.
Other serious risks: Potential complications include liver problems, heart failure worsening, and certain malignancies. Individual risk depends on several factors, and these concerns should be discussed with a healthcare professional.
Patients are generally assessed for tuberculosis and evaluated for other relevant infections before treatment. Medical professionals may also recommend blood tests and ongoing monitoring based on individual circumstances.
Adalimumab can interact with certain medicines, particularly those that also affect immune function. Before starting treatment, patients should provide their healthcare professional with a complete list of prescription medicines, over the counter products, supplements, and vaccinations they receive.
Some combinations may increase the risk of infections or other adverse effects. Medicines should not be stopped or combined without appropriate medical guidance.
Other TNF blockers: Combining adalimumab with other TNF inhibitors, such as etanercept or infliximab, is generally not recommended because of increased risks, including serious infections.
Biologic immunomodulators: Combining adalimumab with certain biologic medicines, including anakinra or abatacept, may increase the risk of serious infections and is generally avoided for the relevant indications.
Other immunosuppressants: Medicines such as methotrexate, corticosteroids, or other immune-suppressing treatments may affect infection risk. Some combinations are used under medical supervision, so their suitability depends on the condition and treatment plan.
Live vaccines: Live vaccines are generally avoided during adalimumab treatment. Patients should discuss vaccination timing and appropriate alternatives with their healthcare professional.
Medicines requiring monitoring: Other treatments may require additional monitoring because of overlapping adverse effects or changes in disease control.
Patients should seek urgent medical assessment for severe breathing difficulties, facial or throat swelling, or signs of a serious infection. Persistent fever, unexplained weight loss, unusual bruising, or new neurological symptoms should also be reported promptly.
Understanding adalimumab risks and interactions helps patients participate in treatment decisions and recognize symptoms that require attention. Healthcare professionals can assess individual risk factors, review medication combinations, and determine appropriate monitoring throughout therapy. Patients should follow their prescribed treatment plan and consult their healthcare team before making changes to medication or vaccination schedules.